<span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">atezolizumab based treatment</span> <span style="margin-left: 3em;">atezolizumab plus bevacizumab plus carboplatin plus paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">atezolizumab plus carboplatin plus nab-paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">atezolizumab plus carboplatin plus paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">VEGF(R) inhibitor</span> <span style="margin-left: 1em;">bevacizumab based treatment</span> <span style="margin-left: 2em;">bevacizumab plus carboplatin and paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (3) progression or deaths (PFS) (3) objective responses (ORR) (2) DOR (2) AE (any grade) (2) TRAE (any grade) (2) SAE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) TRAE (grade 3-4) (2) AE (grade 3-4) (2) TRAE leading to death (grade 5) (2) AE leading to death (grade 5) (2) STRAE (any grade) (2) Decreased appetite TRAE (grade 3-4) (3) Alopecia TRAE (grade 3-4) (2) Thrombocytopenia TRAE (grade 3-4) (2) Neutropenia TRAE (grade 3-4) (2) Fatigue TRAE (grade 3-4) (2) Nausea TRAE (grade 3-4) (2) Vomiting TRAE (grade 3-4) (2) Anaemia TRAE (grade 3-4) (2) Rash TRAE (grade 3-4) (2) Diarrhoea TRAE (grade 3-4) (2) Asthenia TRAE (grade 3-4) (2) Constipation TRAE (grade 3-4) (2) Paraesthesia TRAE (grade 3-4) (1) Leucopenia TRAE (grade 3-4) (1) Myalgia TRAE (grade 3-4) (1) Hypophysitis TRAE (grade 3-4) (1) Adrenal insufficiency TRAE (grade 3-4) (1) Diabetes TRAE (grade 3-4) (1) Pancreatitis TRAE (grade 3-4) (1) Colitis TRAE (grade 3-4) (1) Increased ALT TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Hepatitis TRAE (grade 3-4) (1) Nephritis TRAE (grade 3-4) (1) Myositis TRAE (grade 3-4) (1) Peripheral neuropathy TRAE (grade 3-4) (1) Dysgeusia TRAE (grade 3-4) (1) Stomatitis TRAE (grade 3-4) (1) Epistaxis TRAE (grade 3-4) (1) Hypertension TRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (1) Sepsis TRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (1) Hyperthyroidism TRAE (grade 3-4) (1) Arthralgia TRAE (grade 3-4) (1) Pneumonitis TRAE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (1) Rash AE (grade 3-4) (1) Increased ALT AE (grade 3-4) (1) Increase AST AE (grade 3-4) (1) Pyrexia AE (grade 3-4) (1) Weight decreased AE (grade 3-4) (1) Pruritus AE (grade 3-4) (1) Nausea AE (grade 3-4) (1) Vomiting AE (grade 3-4) (1) Constipation AE (grade 3-4) (1) Abdominal pain AE (grade 3-4) (1) Fatigue AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1) Headache AE (grade 3-4) (1) Decreased appetite AE (grade 3-4) (1) Dyspnoea AE (grade 3-4) (1) Hypertension AE (grade 3-4) (1) Hypothyroidism AE (grade 3-4) (1) Arthralgia AE (grade 3-4) (1) Stomatitis AE (grade 3-4) (1) Hyperthyroidism AE (grade 3-4) (1) Blood creatinine increased AE (grade 3-4) (1) Dysgeusia AE (grade 3-4) (1) Anaemia AE (grade 3-4) (1) Thrombocytopenia AE (grade 3-4) (1) Neutropenia AE (grade 3-4) (1) Dizziness AE (grade 3-4) (1) Dry skin AE (grade 3-4) (1) Peripheral oedema AE (grade 3-4) (1) Epistaxis AE (grade 3-4) (1) Colitis AE (grade 3-4) (1) Cough AE (grade 3-4) (1) Back pain AE (grade 3-4) (1) Febrile neutropenia AE (grade 3-4) (1) Leucopenia AE (grade 3-4) (1) Pneumonitis AE (grade 3-4) (1) Sepsis AE (grade 3-4) (1) Peripheral neuropathy AE (grade 3-4) (1) Infusion-related reaction AE (grade 3-4) (1) Myalgia AE (grade 3-4) (1) Rash maculopapular AE (grade 3-4) (1) hepatitis (Autoimmune) AE (grade 3-4) (1) Alopecia AE (grade 3-4) (1) Paraesthesia AE (grade 3-4) (1) Gastritis AE (grade 3-4) (1) Pancytopenia (AE grade 3-4) (1) Agranulocytosis (AE grade 3-4) (1) Diabetes mellitus AE (grade 3-4) (1) Pneumonia AE (grade 3-4) (1) Peripheral sensory neuropathy AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 IMpower-130 (all population), 2019 1 IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel
0.89 [0.68; 1.17] 0.89 [0.68;1.17]atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel
0.89 [0.68; 1.17] atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better
0.76 [0.63; 0.92] 0.76 [0.63;0.92]atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better
0.76 [0.63; 0.92] atezolizumab plus carboplatin plus paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
1.12 [0.85; 1.46] 1.12 [0.85;1.46]atezolizumab plus carboplatin plus paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
1.12 [0.85; 1.46] atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
0.85 [0.71; 1.02] 0.85 [0.71;1.02]atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
0.85 [0.71; 1.02] bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better
1.32 [1.08; 1.60] 1.32 [1.08;1.60]bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better
1.32 [1.08; 1.60] bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel
1.18 [0.98; 1.42] 1.18 [0.98;1.42]bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel
1.18 [0.98; 1.42] bevacizumab plus carboplatin and paclitaxel atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus carboplatin plus paclitaxel direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C bevacizumab plus carboplatin and paclitaxel atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus carboplatin plus paclitaxel bevacizumab plus carboplatin and paclitaxel --- NA 1.32 1.08; 1.601.18 0.98; 1.42atezolizumab plus carboplatin plus nab-paclitaxel NA --- NA NA atezolizumab plus bevacizumab plus carboplatin plus paclitaxel 0.76 0.63; 0.92NA --- 0.89 0.68; 1.17atezolizumab plus carboplatin plus paclitaxel 0.85 0.71; 1.02NA 1.12 0.85; 1.46---
pathologies: 165
- treatments: 744
result logic